Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
Cancer Research and Treatment. 2015;47(4):781-789 
A Multicenter, Randomized, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Combination Docetaxel and Carboplatin and Sequential Therapy With Docetaxel Then Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Yearbook of Oncology. 2012;2012:103-104
O-4 A randomized phase II study of docetaxel versus docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first line chemotherapy
Lung Cancer. 2003;41:S5
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy
Yearbook of Oncology. 2008;2008:219-221
A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-?2a in patients with advanced malignant melanoma
Cancer Immunology Immunotherapy. 1994;38(6):379-384
5054 Safety and efficacy of the combination of trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: phase II results
European Journal of Cancer Supplements. 2009;7(2):276
Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
Yearbook of Medicine. 2011;2011:120-121
Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
Yearbook of Oncology. 2011;2011:32-33
P92 Docetaxel versus epirubicin/cyclophosphamide (EC)as first-line therapy in metastatic breast cancer (MBC): results from the randomized phase II TIPP study
The Breast. 2005;14:S41
Docetaxel with epirubicin as first line chemotherapy in metastatic breast cancer (MBC). Final results of a Phase II study
European Journal of Cancer. 2002;38(11):S68